



Sudan University of Science and Technology
College of Graduate studies

**Evaluation of Some Coagulation parameters Among Sudanese
women with Breast Cancer- Khartoum state**

**تقدير بعض معالم التجلط لدى النساء السودانيات المصابة بسرطان الثدي
ولاية الخرطوم**

A dissertation submitted in partial fulfillment of the requirement of M.Sc
degree in Hematology and Immunohematology

Submitted By:

Mohammed Ahmed Ibrahim Elobied
(B.Sc. in hematology – University of Khartoum 2001)
(Qualifying year 2004 – 2005)

Supervisor:

Dr. Mohi Eldein Abass Abdalla Elsayid
Ph.D (Hematology)
Assistant professor (SUST)

June 2012

الآية الكريمة

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قال تعالى:

(قُلْ أَرَأَيْتُمْ إِنْ كَانَ مِنْ عِنْدِ اللَّهِ ثُمَّ كَفَرُتُمْ بِهِ مِنْ أَصْلِهِ مِنْ هُوَ فِي شِقَاقٍ بَعِيدٍ (52)

سَرِّهِمْ آيَاتِنَا فِي الْأَفَاقِ وَفِي أَنفُسِهِمْ حَتَّىٰ يَبْيَنَ لَهُمْ أَنَّهُ الْحَقُّ أَوْ كُمْ يَكْفِ سِرِّكَ أَنَّهُ عَلَىٰ

كُلِّ شَيْءٍ شَهِيدٌ (53) أَلَا إِنَّهُمْ فِي مَرْيَةٍ مِنْ لِقَاءِ رَبِّهِمْ أَلَا إِنَّهُ بِكُلِّ شَيْءٍ مُحِيطٌ (54)

صدق الله العظيم

سورة فصلت الآيات 52 - 54

Dedication

To my darling parents whose always support me and encourage me to success.

To my wife, children, brothers, sisters for their endless help and motivation.

To my friend, who gave me the possibility of completing this thesis?
To everyone who help me to learn new things and to reach this level.

Acknowledgments

From the formative stages of this thesis, to the final draft, I owe an immense debt of gratitude to my supervisor, Dr. Mohi Eldein Abass Abdalla Elsayid. For his advice and careful guidance were invaluable; I would also like to thank those who agreed to be interviewed, for, without your time and cooperation, this project would not have been completed. For their efforts and assistance, a special thanks as well to my wife, son, daughter, family doctors, colleagues, sisters, brothers, wife, children. Finally, I would be remiss without mentioning to whose extreme generosity will be remembered always. To each of the above, I extend my deepest appreciation.

Abstract

This is an analytical case control study conducting during the period from March to May 2012 at Radiation and Isotope center in Khartoum. The aim of this study was to evaluate of some coagulation parameters; prothrombin time (PT) activated partial thromboplastin time (APTT), Fibrinogen, and D-dimer in Sudanese women with breast cancer. Seventy women with breast cancer were informed about the study and agreement of participant was obtained. A questionnaire was used to collect data about age, tribe, duration, family history and state. Thirty five healthy participant (control healthy women) were also informed and their blood samples were collected and used as control. Blood samples (5ml) were taken from both patient and control in trisodium citrate anticoagulant containers, then centrifuged the samples to harvest platelets poor plasma for measurement of PT, APTT, Fibrongen and D-dimer by hopistex coagulameter and i-chroma reader. Statistical analysis show that the mean of PT, Fibrongen and D-dimer (14.1 sec), (690 gm/l) and (639 ng/ml) respectively were significantly higher (P.value < 0.05) than the control mean of PT, Fibrongen and D-dimer (12.3 sec) , (270 gm/l) and (202 ng/ml) respectively, and show no statistical difference between APTT in case and control (P.value > 0.05). The study revealed that there is no any significant difference between case and control according to the age and duration of disease. I conducted from this study that woman with breast cancer in high risk of venous thrombosis.

ملخص الدراسة

هذه الدراسة مقطعيّة وصفية (حالة وحالة ضابطة)، تم إجراؤها في الفترة من مارس 2012 إلى يونيو 2012 بمستشفى الذرة ولاية الخرطوم. وكان الهدف منها تقدير زمن الثرومبين زمن الثرومبوبلاستين الجزيء المنشط وتركيز الفبرينوجين والذي دائمًا لدى النساء المصابات بسرطان الثدي وتم ملئ الإسٌٌتبيان لمعرفة العمر، فترة المرض، التاريخ المرضي للعائلة والسكن. وشملت الدراسة على 70 من النساء السودانيات المصابات بسرطان الثدي وخمسة ثلاثون عينة من نساء أصحاء كعينة ضبط، اخذت 5 مل من الدم الوريدي من كل مشاركة في هذه الدراسة وفي محلول سترات الصوديوم الثلاثي وتم فصل البلازماء لإجراء قيم التجلط بإستخدام جهاز (Hopistie coagulameter, i-chroma reader) احصائيًا بواسطة برنامج الحزم الاحصائية للعلوم الاجتماعية الاصدار 11,5 وكانت النتائج في النساء المصابات نتيجة متوسط زمن البروثرومبين وزمن الثرومبوبلاستين الجزيئي المنشط، الفبرينوجين والذي دائمًا (14,1 33,1 ثانية) (690 غرام/مل) و (639 نانوغرام/مل) على التوالي وعند مقارنتها مع مجموعة الضبط (12,3)، (32 ثانية) (270 غرام/مل) و (202 نانوغرام/مل) على التوالي، القيم أعلى تظهر فروق ذات دلالة احصائية بين النساء المصابات بسرطان الثدي والعينة الضابطة في متوسطات البروثرومبين، الفبرينوجين والذي - ديمير (القيمة المعنوية في جميع الاختبارات اقل من 0,05)، بينما لا يوجد فرق ذو دلالة احصائية في متوسط زمن الثرومبوبلاستين الجزيء المنشط. وأوضحت الدراسة أنه لا يوجد فروقات بين العمر وفترة المرض. استنتجت من هذه الدراسة أن النساء ذوات سرطان الثدي في خطر التخثر الوريدي.

List of Contents

No.	Contents	Page
1.	الآية	I
2.	Dedication	II
3.	Acknowledgement	III
4.	Abstract (English)	IV
5.	Abstract (Arabic)	V
6.	List of contents	VI
7.	List of Tables	X
8.	List of Figures	XI
9.	List of abbreviations	XII

Chapter One

Introduction and Literature review

1.1	introduction	1
1.2	Literature review	2
1.2.1	Over view of hemostasis	2
1.2.1.1	components of hemostatic system	2
1.2.1.2	Hemostasis mechanism	6
1.2.1.2.1	Primary hemostasis	7
1.2.1.2.2	Mechanism of primary hemostasis	7
1.2.1.2.3	Secondary hemostasis	9
1.2.1.2.4	Coagulation factors	10

1.2.1.2.5	Mechanism of secondary hemostasis	12
1.2.1.3	Anticoagulant protein	14
1.2.1.4	Fibrinolysis	15
1.2.1.5	Hypercoagulability (Thrombophilia)	16
1.2.1.5	Antithrombin Deficiency	17
1.2.2	Breast cancer	18
1.2.2.1	Physiology of the breast cancer	18
1.2.2.2	structure of the breast	18
1.2.2.3	Breast cancer	18
1.2.2.4	Incidence of the breast cancer	18
1.2.2.5	Incidence of the breast cancer in Sudan	19
1.2.2.6	Classification of Breast Cancer	20
1.2.2.7	Staging	20
1.2.2.8	Inflammatory breast cancer	21
1.2.2.9	Recurrent/ Relapsed	21
1.2.2.10	Histopathology	22
1.2.2.11	Grade	22
1.2.2.12	Receptor status of breast cancer	22
1.2.2.13	DNA Microarrays	23
1.2.2.14	Types of breast cancer	23
1.2.2.15	Rare types of breast cancer	24
1.2.2.16	Symptoms of breast cancer	26
1.2.2.17	Risk factors of breast cancer	27

1.2.2.18	Pathophysiology of the breast cancer	28
1.2.2.19	Breast cancer susceptible genes	28
1.2.2.20	Prevention of breast cancer	29
1.2.2.21	Diagnosis of breast cancer	29
1.2.2.22	Treatment of breast cancer	30
1.2.2.23	Prognosis of the breast cancer	30
1.2.2.24	Venous thromboembolism in cancer	32
1.2.3	Fibrinogen degradation products and d-dimers in patients with breast carcinoma	33
1.2.4	Plasma fibrin D-dimer levels correlate with tumour volume	33
1.2.5	Plasma d-Dimer Levels in Operable Breast Cancer	33
1.2.6	Epidemiology and pathophysiology of cancer	33
1.2.7	Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer	33
1.3	Rational	34
1.4	Objectives	35

Chapter Two

Materials and Methods

2.1	Study approach	36
2.2	Study design	36
2.3	Study areas	36
2.4	Study population	36

2.5	Study duration	36
2.6	Ethical consideration	36
2.7	Data collection	36
2.8	Inclusion criteria	36
2.9	Exclusion criteria	36
2.10	Data processing	36
2.11	Data presentation	36
2.12	Sampling	37
2.12	Sample	37
2.14	Methodology	37
2.15	Statistical analysis	40

Chapter Three

Results

Chapter Four

Discussion, Conclusion and Recommendations

4.1	Discussion	45
4.2	Conclusion	47
4.3	Recommendations	48
	Reference	49
	Appendices	53

List of figures

No.	Titles	Page
Figure (3.1)	The number of case and control	57
Figure (3.2)	The mean of pt on the case and the control.	57
Figure (3.3)	The mean of APTT on the case and the control.	58
Figure (3.4)	The mean of fibrinogen on the case and the control	58
Figure (3.5)	The mean of D-Dimer on the case and the control.	59
Figure (3.6)	The number of case according to age group.	59
Figure (3.7)	The mean of PT according to age groups	60
Figure (3.8)	The mean of APTT according to age groups	60
Figure (3.9)	The mean of fibrinogen according to age groups	61
Figure (3.10)	The mean of D- Dimer according to age groups	61
Figure (3.11)	The number of case according to the duration group	62
Figure (3.12)	The mean of PT according to duration groups	62
Figure (3.13)	The mean of APTT according to duration groups	63
Figure (3.14)	The mean of fibrinogen according to duration groups	63
Figure (3.15)	The mean of D- Dimer according to duration groups	64

List of tables

No.	Titles	Page
Table (1.1)	frequency of breast cancer in Sudan 2003 – 2011	19
Table (1.2)	incidence of breast cancer according to age group	20
Table (3.1)	Comparison of mean,SD, P.value between case and control	41
Table (3.2)	comparison of mean,SD, P.value due to age groups	42
Table (3.3)	comparison of mean,SD, P.value due to duration groups	43
Table (3.4)	The (PT, APTT, FIBRINOGEN,D DIMER) means, medians, modes, SD, minimum, maximum	44

List of Abbreviations

No.	Abbreviations	Words of abbreviations
1	PA	Plasminogen activator
2	ADP	Adenosine disulphate
3	PG	Prostaglandin
4	PDGF	Platelets derived growth factor
5	Gp	Glycoprotein
6	ATP	Adenosine triphosphate
7	CD	Cluster differentiation
8	GTP	Guanosine 5triphosphate
9	GDP	Guanosine diphosphate
10	vWF	Von willebrand factor
11	TXA2	Thromboxane A2
12	cAMP	Cyclic adenosine monophosphate
13	HMWK	High molecular weight kininogen
14	KD	Kilo Dalton
15	TF	Tissue factor
16	PT	Prothrombin time
17	TFPI	Tissue factor pathway inhibitor
18	F	Factor
19	TAT	Thrombin_anti thrombin
20	AT	Anti thrombin
21	tPA	Tissue plasminogen activator
22	PA1	Plasminogen activator inhibitor _1
23	TNM	Tumor ,lymph node, metastasis
24	ER	Estrogen receptor
25	PR	Progesterone receptor
26	IBC	Inflammatory breast cancer

27	DCIS	Ductal carcinoma in situ
28	HRT	Hormone replacement therapy
29	DNA	Deoxy nucleic acid
30	BRCA1	Breast cancer type 1
31	CP	Cysteine protease cancer procoagulant
32	IL	Interleukin
33	TM	Thrombomodulin
34	APTT	Activated partial thromboplastin time
35	RICK	Radiation and Isotope Center in Khartoum
36	BJC	British journal of cancer